Spexis AG (SWX: SPEX)

Market Cap	4.40M
Revenue (ttm)	595.35K
Net Income (ttm)	-19.62M
Shares Out	67.66M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,260
Open	0.0500
Previous Close	0.0570
Day's Range	0.0500 - 0.0570
52-Week Range	0.0100 - 1.0600
Beta	0.32
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 11, 2025

About Spexis AG

Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixaforti...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jeffrey Wager
• Employees: 50
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: SPEX

Financial Performance

In 2023, Spexis AG's revenue was 595,350, a decrease of -59.64% compared to the previous year's 1.48 million. Losses were -19.62 million, 5.74% more than in 2022.